Semaglutide as a potential neuroprotective agent for neurological and neurodegenerative disorders: Mechanisms, preclinical evidence, and translational challenges and opportunities.

A timely synthesis of where semaglutide's neuroprotection story stands after the EVOKE setback. The picture is genuinely mixed: preclinical models and observational dementia-risk data point one way, while the phase 3 trials in early Alzheimer's missed their primary cognitive endpoints even as p-tau and inflammation biomarkers improved. The authors' framing — biomarker engagement without demonstrated clinical benefit, possibly a matter of timing or CNS exposure — is a fair reading of the results, and the open questions they list are the right ones.